Merck KGaA sees slight increase in 2015 adj core earnings

DARMSTADT, March 3 (Reuters) - Germany's Merck KGaA said underlying core earnings would stagnate or grow only slightly this year as it spends money on developing a new immunotherapy against cancer and as its injectable multiple sclerosis drug Rebif faces strong competition from oral treatments.